Breakthrough in Cancer Treatment! New Antibody Hv1Lt1 Debuts
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
[New Antibody Hv1Lt1 Opens New Directions for Cancer Treatment]
The antibody Hv1Lt1 can prevent the activation of the DKK1-CKAP4 pathway in pancreatic cancer and other types of cancer, effectively inhibiting tumor growth and enhancing the efficacy of chemotherapy, offering new hope for treatment.
Key Data:
- Tumor growth was effectively prevented in mouse experiments.
- Enhanced the effects of chemotherapy, further inhibiting cancer cells.
- Provides a new strategy for cancer treatment.
For more details, please visit: https://tinyurl.com/28lx2sy3
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4